CRISPR Enhances Cancer Immunotherapy (IMAGE)
Caption
Scientists at Washington University School of Medicine in St. Louis now have used the gene-editing technology CRISPR to engineer human T cells that can attack human T cell cancers. They also engineered the T cells to eliminate a potentially dangerous side effect called graft-versus-host disease, where the therapeutic T cells that kill the cancer also attack the patient's organs. John DiPersio, MD, PhD, (right) leads a team developing an "off-the-shelf" CAR-T immunotherapy for hard-to-treat T cell cancers. A new study evaluates the approach in mice with human T cell acute lymphoblastic leukemia. Shown is DiPersio working with co-author Armin Ghobadi, MD, in the lab.
Credit
Huy Mach
Usage Restrictions
None
License
Licensed content